--- title: "KYE™ Pharma AI Authority™ — proof for every pharma AI action · KYE Protocol™" description: "Pharma teams run AI across R&D, clinical, safety and quality; KYE Protocol™ proves whether each pharma AI action — a synthesis order, a protocol decision, a signal disposition, a batch or result release — was authorised, purpose-bound, evidenced, replayable and final. A validated model is not an authorised action." url: https://kyeprotocol.com/solutions/pharma-ai-authority/ lang: en source: "KYE Protocol" --- > Pharma teams run AI across R&D, clinical, safety and quality; KYE Protocol™ proves whether each pharma AI action — a synthesis order, a protocol decision, a signal disposition, a batch or result release — was authorised, purpose-bound, evidenced, replayable and final. A validated model is not an authorised action. # Pharma AI Authority™ — proof for every pharma AI action Pharma teams run AI across discovery, clinical, safety and quality. KYE Protocol™ proves whether each pharma AI action — a nucleic-acid synthesis order, a trial-protocol decision, a safety-signal disposition, a batch or clinical-result release — was authorised, purpose-bound, evidenced, replayable and final. A model can be validated to GxP and still act without authority. KYE™ is not another lab platform, CTMS, safety database or model-validation tool. It is the authority layer underneath them: the runtime control point that decides whether an AI agent's proposed pharma action has authority, then emits a signed, replayable record. GxP asks whether the system is validated; KYE™ asks whether this specific action was authorised, by whom, under which SOP version — the answer a regulator can replay years later. [Start a pharma authority pilot](https://kyeprotocol.com/poc/) [See the pharma agents](https://kyeprotocol.com/governed-agents/) ## The line: a validated model vs. an authorised action Your quality system validates the software and qualifies the model. KYE™ governs the action boundary: the instant an AI agent proposes a consequential pharma action, KYE™ checks actor, mandate, purpose, data scope, SOP version, policy, risk, human sign-off and finality, then returns `allow` / `deny` / `require_approval` / `suspend`. ### Your quality system asks Is the software validated and the model qualified for its intended use under GxP? ### KYE™ asks When the AI acts, can you prove who authorised it, under what mandate, purpose, SOP version and evidence — and whether it became final? The authority questions are banking-grade for regulated pharma: Is this agent allowed to release a batch, disposition a safety signal, or approve a protocol deviation? Who delegated that authority? Is the action advisory, or did it update a validated system of record? Can the decision be replayed for an inspector, sponsor, ethics committee or litigation years later? Every KYE™ answer maps to a real regulatory spine and a signed evidence record. ## Already shipped: four pharma & life-sciences Authority Packs™ You do not adopt a new framework — you bind the packs that already exist. Each pack governs a pharma action vertical against its real regulatory spine: EMA GVP, ICH E6(R3) GCP, FDA 21 CFR Part 11, OECD GLP, FDA 21 CFR Part 58 and nucleic-acid synthesis screening. Pick the verticals your AI touches. [**KYE™ Clinical AI Governance Pack™** Clinical trial conduct and clinical-decision authority under ICH E6(R3) GCP and 21 CFR Part 11 — protocol deviations, eligibility and result release.](https://kyeprotocol.com/foundry/clinical-ai-governance-pack/) [**KYE™ Biopharma Pharmacovigilance Authority Pack™** Post-market drug-safety reporting authority under EMA GVP, MHRA and 21 CFR Part 11 — signal disposition and case processing.](https://kyeprotocol.com/foundry/biopharma-pharmacovigilance-authority-pack/) [**KYE™ Bio-Chem Governance Pack™** Nucleic-acid synthesis, sequence-of-concern screening and biosecurity dispositions across discovery and research.](https://kyeprotocol.com/foundry/bio-chem-governance-pack/) [**KYE™ Genomics & Biosecurity Authority Pack™** Genomic-data sharing, consent and sequence-screening authority at the genomic action boundary.](https://kyeprotocol.com/foundry/genomics-biosecurity-authority-pack/) ## Five pharma governed agents, each authority-checked at the action boundary Where you deploy AI, KYE™ ships the per-action authority agents that govern it. Each is a first-class principal with a delegation chain, a [KYE™ Evidence Pack™](https://kyeprotocol.com/evidence-pack/) and a Replay-Proof™ trail — so a quality lead, inspector or sponsor can reconstruct any decision offline. - [Clinical Action Authority Agent](https://kyeprotocol.com/governed-agents/clinical-action-authority-agent/) — accept, deny or adjust a clinical decision - [Clinical Trial Conduct Authority Agent](https://kyeprotocol.com/governed-agents/clinical-trial-conduct-authority-agent/) — protocol, eligibility and deviation authority - [Drug Discovery Research Authority Agent](https://kyeprotocol.com/governed-agents/drug-discovery-research-authority-agent/) — nonclinical study-data-integrity authority - [Genetic Sequencing Authority Agent](https://kyeprotocol.com/governed-agents/genetic-sequencing-authority-agent/) — synthesis-order and sequence-of-concern screening - [Pharmacovigilance Action Authority Agent](https://kyeprotocol.com/governed-agents/pharmacovigilance-action-authority-agent/) — post-market safety-signal disposition [Browse the governed agents](https://kyeprotocol.com/governed-agents/) ## For pharma AI platforms & digital R&D labs If you run an AI platform across discovery, clinical operations, safety or quality, KYE™ is the authority layer beneath your agents. Your platform orchestrates the science and the workflow; KYE™ proves the workflow stayed inside authority. This governs the decision, not the bench — KYE™ never runs the assay, the trial or the model. The integration is a runtime check: your agent proposes a consequential action, KYE™ evaluates actor, mandate, purpose, data scope, SOP version, policy, risk, human sign-off and finality through the [Evidence Pack™](https://kyeprotocol.com/evidence-pack/) chain, and returns a verdict your platform continues, escalates or blocks on. A digital R&D lab can execute; KYE™ decides whether execution has authority. ## For CROs, sponsors & regulatory affairs If you run trials, own safety, or file with regulators, KYE™ governs every consequential AI action across the study and the submission. A validated summary is not the same as an authorised release, and an AI can draft a perfect narrative and still lack authority to disposition a case or release a result. KYE™ binds each agent to a mandate and a purpose, then gates the moment it tries to disposition a safety signal, approve a protocol deviation, release a clinical result or advance a submission decision. Every gated action emits a signed record that an inspector, sponsor, ethics committee or litigation can replay — so "the AI did it" is never the end of the trail. ## One authority spine under every pharma AI action Every pack and agent above resolves to the same runtime primitives — so you govern discovery, clinical, safety and quality through one control point, not four. KYE™ reuses these primitives; it never reimplements them per vertical. ### Authority Gateway™ Runtime allow / deny / require approval / suspend at the action boundary. ### Purpose Permission™ Binds each action to a permitted purpose and data scope. ### Decision Map™ Inputs, policy, model, human override, verdict and obligations for one decision. ### [Evidence Pack™](https://kyeprotocol.com/evidence-pack/) Signed proof of actor, mandate, data, purpose, SOP version, approval and finality. ### Replay-Proof™ Offline reconstruction of why an action was allowed or blocked, from public keys alone. ### Entity & Principal Registry Investigator, sponsor, AI agent, service account, vendor and workflow as governed principals. The result is one provable answer for every patient- and product-impacting action: who had authority, for what purpose, with what evidence, and whether it became final under Authority Finality™. [Start a pharma authority pilot](https://kyeprotocol.com/poc/) [Explore the pharma packs](https://kyeprotocol.com/foundry/clinical-ai-governance-pack/) Canonical KYE™ surfaces referenced on this page: [KYE Protocol™](https://kyeprotocol.com/) · [Purpose Permission](https://kyeprotocol.com/glossary/).